NICE Endorses Obecabtagene Autoleucel Therapy f...

By João L. Carapinha

November 25, 2025

NICE Backs Obecabtagene Autoleucel The National Institute for Health and Care Excellence (NICE) recommended obecabtagene autoleucel therapy, a UK-dev...
Accelerating Access to Latin America Innovative Therapies Through Collaborati...
Rethinking HEOR Market Access Integration: A Call for Early Engagement Before...
Patient-Reported Outcomes Trends in Clinical Trials: Insights from 2008-2023
Addressing AI Polyp Detection Gaps: A Roadmap for Evidence Generation and NHS...
Health Investment Returns: Harnessing Health as a Strategic Economic Asset
Emblaveo MDR Infections: Evaluating a New Solution for Multidrug-Resistant Gr...
Promising Advances in TNBC Treatment: Sacituzumab Govitecan in First-Line The...
Interchangeable Biosimilar Approval: FDA Greenlights Poherdy as First to Perjeta
HIV Therapy Advancements: Promising Results from Bictegravir/Lenacapavir Comb...
Navigating Targeted Therapy Access: Innovations and Challenges in High-Cost T...
Weight Loss: Advances in Hormone-Based Obesity Treatments
NICE NHS Prioritization: A Strategic Shift to Address Healthcare Challenges